Reviewing Evidence-Based Rehabilitation for Voice and Movement in Parkinson Disease Care
June 27th 2025Cynthia Fox, PhD, CCC-SLP, CEO and co-founder of LSVT Global, discussed the evolution of rehabilitative therapies in PD and stressed early referrals for speech, physical, and occupational therapy.
Phase 2 SUNRISE-PD Trial to Test BioVie‘s Bezisterim for Early-Stage Parkinson Disease
June 27th 2025The design of a phase 2 study, presented at ATMRD 2025, highlighted the trial’s patient-focused approach, allowing patients with Parkinson disease to complete visits either at home or in a clinic.
Patient and Clinician Perspectives on Empathy in Parkinson Disease Care: Daniel Irizarry, MD
June 27th 2025The medical advisor at Tactical Medical Solutions shared insights from both clinical and personal perspectives on the importance of empathy and active listening in managing Parkinson disease. [WATCH TIME: 3 minutes]
Balancing MS Relapse Risk With Personalized Therapy Decisions: Gabrielle Macaron, MD
June 26th 2025The assistant professor in the Department of Neuroscience at Université de Montréal discussed the importance of weighing the risks of multiple sclerosis against treatment risks, emphasizing individualized care. [WATCH TIME: 4 minutes]
Using AI to Assist in Identifying Cardiovascular Risk in Patients With Migraine
June 26th 2025Chia-Chun Chiang, MD, associate professor of neurology at Mayo Clinic Rochester, discussed how AI-based ECG and imaging tools can aid in predicting stroke and cardiovascular outcomes in patients with migraine.
NeuroVoices: Stewart Tepper, MD, on Understanding Newly Approved STS101 for Acute Migraine
June 25th 2025The professor of neurology at the Geisel School of Medicine at Dartmouth broke down the clinical utility, supporting data, and practical use cases for STS101, a newly approved nasal powder formulation of dihydroergotamine for acute migraine.
Understanding ALKS 2680’s Wake-Promoting Effects Through qEEG: Julia Chapman, PhD
June 24th 2025The postdoctoral researcher at the Woolcock Institute of Medical Research highlighted EEG-based evidence supporting ALKS 2680's wake-promoting effects in patients with narcolepsy and idiopathic hypersomnia. [WATCH TIME: 3 minutes]
Patients Voicing Key Needs for Migraine Care and Advocacy: Elizabeth W. Leroux, MD, FRCPC
June 24th 2025The neurologist and headache specialist at the Montreal Neurological Clinic spoke about a recent national survey presented at AHS 2025 that revealed insightful patient perspectives in migraine. [WATCH TIME: 5 minutes]
European Commission Approves Efgartigimod Subcutaneous Injection for Forms of CIDP
June 24th 2025Efgartigimod alfa SC is now approved in Europe for patients with chronic inflammatory demyelinating polyneuropathy, following a positive recommendation from the Committee for Medicinal Products for Human Use.
What Newly Approved STS101 Brings to Migraine Treatment Landscape: Stewart Tepper, MD
June 23rd 2025The professor of neurology at the Geisel School of Medicine at Dartmouth broke down the FDA approval of STS101, a new DHE nasal powder, and its implications for acute migraine care. [WATCH TIME: 7 minutes]
Clinicians Express Growing Optimism in ALS Research and Treatment Advancements
June 23rd 2025Experts in ALS care and research shared their optimism about emerging treatments, aiming to deepen scientific understanding, and the potential role of advocacy in accelerating progress. [WATCH TIME: 4 minutes]
Exploring Cognitive Difficulties in Migraine: Aligning Subjective and Objective Findings
June 22nd 2025Laura Sebrow, PhD, a post doctoral neuropsychology fellow at North Shore University Hospital, discussed the relationship between patients’ reported cognitive difficulties and measurable cognitive performance during different migraine phases.
Targeting A3AR in Trigeminal Neuropathic Pain: A Promising Approach for an Unmet Clinical Need
June 21st 2025Marcela Romero-Reyes, DDS, PhD, FAHS, director of the Brotman Facial Pain Clinic at the University of Maryland, discussed a promising and potentially safer therapeutic approach for managing trigeminal neuropathic pain.